A Review on Transdermal Patch of Clotrimazole for Fungal infection

Abstract

One of the most prevalent dermatological issues in the world today is fungal skin infections. It's According to research; 40 million people have fungal infections. Surface-level and Skin, keratinous tissues, and mucous membranes are all impacted by subcutaneous fungal infections. What superficial candidiasis of the mouth, skin, or genital tract, dermatophytic infections, and infections brought on by Malassezia folliculitis and pityriasis versicolor are the primary conditions caused by Malassezia. circumstances. One of two possible causes of systemic fungal infections is an opportunistic organism that infects an at-risk host, be connected to a more invasive organism, or be unique to a particular geographical region. These consist of. High bioavailability, lack of hepatic first-pass metabolism, consistent drug plasma concentrations and the non-invasiveness of the treatment. The primary barrier to the stratum corneum, the skin's outermost layer, penetrates drug molecules. As a result, overcoming this layer to improve transdermal drug delivery (TDD) is a prime area of research. curiosity. The purpose of this review article is to offer coverage and commentary on the most recent developments. in methods for improving TDD.

Keywords

Drug-in-Adhesive, Systemic, Transdermal Patch, Controlled Drug Delivery, TDDS Pharmacotherapy, 3D printing, skin penetration, delivery, and patient compliance

Introduction

 

 

 

Dermis:

The connective tissue matrix that makes up the 3–5 mm thick layer of dermis contains blood vessels, lymph vessels, and nerves. The majority of molecules that penetrate the skin barrier find a sink in capillaries, which extend to within 0.2 mm of the skin's surface.

Hypodermis:

The dermis and epidermis are supported by the hypodermis, or subcutaneous fat tissue. It acts as a place to store fat. This layer offers mechanical protection, nutritional support, and aids in temperature regulation. [14]

Components of transdermal patches:

Polymer Matrix: The drug's release from the device is regulated by the polymer. For a polymer to be utilized in transdermal patches, it must meet the following requirements.

1. The polymer's molecular weight and chemical functionality should allow the particular medication to diffuse and be released through it.
2. The polymer should be stable.
3. The polymer should be nontoxic
4. The polymer should be easily of manufactured
5. The polymer should be inexpensive
6. The polymer and its deagration product must be non-toxic or non-antagonistic to the host.
7. large amounts of the active agent are incorporated into it.

Types of polymers: -

• • Natural polymers: Cellulose derivative, Gelatine, Waxes, Proteins, Gum, Shellac, Natural rubber, starch.
  • Synthetic Elastomers: Hydrin rubber, silicone rubber, Nitrile, Acrylonitrile, Neoprene.
  • Synthetic polymers: Polyvinyl alcohol, polyvinylchloride, polyethylene, polypropylene, polyamide, polyurea, epoxy.

Physiochemical properties:

1. The drug should have a molecular weight less than 1000 Daltons.
2. The drug should have affinity for both lipophilic and hydrophilic phases.
3. The drug should have a low melting point.

Biological properties:

1. The drug should be potent with a daily dose of the order of a few mg/days.
2. The half-life (t½) of the drug should be short.
3. The drug must not produce allergic response.

 

 

Fig. 3: Different parts of transdermal patch Permeation Enhancer:

1. 1. Solvent
   2. Surfactants
   3. Miscellaneous Chemicals
   4. Enhance the permeation

Other excipients: a) Adhesives

Linear: Protect the patch during storage. The linear is removed prior to use.

Backing: Protect the patch from the outer environment. [15-16]

Factors affecting transdermal bioavailability: Two          major  factors affect   the bioavailability of the drug via transdermal routes:

1.Physicochemical Factors: -

Skin hydration: Skin becomes much more permeable when it comes into contact with water. The most crucial element boosting skin penetration is hydration. Humectant is therefore used in transdermal delivery.

Temperature and pH: When the temperature changes, the drug's penetration increases tenfold. Therefore, pH and temperature have a significant impact on drug penetration.

Diffusion coefficient: Penetration of drug depends on diffusion coefficient of drug. Drug concentration: The concentration gradient across the barrier determines the flux, and a higher concentration gradient will result from a greater concentration across the barrier.

Partition coefficient:

Good action requires the optimal partition coefficient (K). High K drugs are unable to exit the lipid layer of the skin. Additionally, medications with low K won't penetrate.

Molecular size and shape:

Molecular weight and drug absorption are inversely correlated; small molecules enter the body more quickly than large ones. Biological Factors:

1. Skin condition
2. Skin age
3. Blood flow
4. Species differences

Types of transdermal patches:

Single-layer Drug-in Adhesive: - The medication is also present in this system's adhesive layer. It is in charge of the drug's release in addition to transporting the entire system to the skin. A backing and a temporary liner encircle the adhesive layer. [17]

 

 

Multi-layer Drug-in-Adhesive: - The single-layer system and the multi-layer drug-in adhesive patch are comparable in that the drug is released by both adhesive layers. Additionally, this patch has a permanent backing and a temporary liner layer. [18]

 

 

Reservoir: - The reservoir transdermal system has a distinct drug layer, in contrast to single-layer and multi-layer drug-in adhesive systems. The adhesive layer separates the drug layer, which is a liquid compartment with a drug suspension or solution. The backing layer supports this patch as well. The rate of release in this kind of system is zero order. [19]

 

 

Matrix: - The drug layer of the Matrix system is a semisolid matrix that holds a drug suspension or solution. In this patch, the drug layer is partially covered by the adhesive layer. [20]

Vapour Patch: - The adhesive layer in this kind of patch releases vapor in addition to holding the different layers together. The vapor patches are brand-new on the market and they release essential oils for up to 6 hours. Vapour patches that reduce the quantity of cigarettes

that one smokes in a month are also available on the market. [21]

Basic Components of TDDS:

•Polymer matrix / Drug reservoir

•Drug

•Permeation enhancers

•Pressure sensitive adhesive (PSA)

•Backing laminates

•Release liner and other excipients like plasticizers and solvents Polymer matrix / Drug reservoir:

The foundation of TDDS is made up of polymers, which regulate the drug's release from the apparatus. Drug dispersion in a liquid or solid-state synthetic polymer base can create a polymer matrix. The polymers used in TDDS should be chemically and biocompatible with the medication and other system elements like PSAs and penetration enhancers. The polymers utilized for TDDS can be classified as: Natural Polymers: e.g. cellulose derivatives, zein, gelatine, shellac, waxes, gums, natural rubber and chitosan etc.

Synthetic Elastomers: e.g. polybutadiene, hydrin rubber, polyisobutylene, silicon rubber, nitrile, acrylonitrile, neoprene, butyl rubber etc.

Synthetic Polymers: such as polyvinyl alcohol, polyvinyl chloride, polyethylene, polypropylene, polyacrylate, polyamide, polyurea, polyvinylpyrrolidone, polymethylmethacrylate, etc.

Drug:

For medications with suitable pharmacology and physical chemistry, the transdermal route is a very appealing choice. Transdermal patches are a great option for medications that go through a lot of first pass metabolism, have a limited therapeutic window, or have a short half-life that makes frequent dosing difficult.

Permeation Enhancers: Three pathways—polar, non-polar, and polar/non-polar—are proposed for drug penetration through the skin. One of these pathways is changed by the enhancers. The secret to changing the polar pathway is to induce solvent swelling or a change in the conformation of proteins. There are two types of methods used to modify the SC's barrier properties in order to improve drug penetration (and absorption) through the skin: (1) chemical methods and (2) physical methods of enhancement. [22]

Chemical Enhancers:

Chemical enhancers act by

1. Increasing the partition coefficient of the drug to promote its release from the vehicle into the skin.
2. Conditioning the SC to promote drug diffusion.
3. Promoting penetration and establish drug reservoir in the SC.

Physical enhancers:

Physical methods of enhancement, such as iontophoresis and ultrasonography (also called phonophoresis or sonophoresis), have been employed to improve the percutaneous penetration (and absorption) of different therapeutic agents.

Pressure sensitive adhesives:

A PSA is a substance that aids in preserving close contact between the skin's surface and the transdermal system. The diffusing medication must not have an impact on the face adhesive in reservoir systems.

Backing Laminate:

The most crucial factor to take into account when designing a backing layer is the material's chemical resistance. The backing with the lowest modulus, or high flexibility, good oxygen transmission, and a high rate of moisture vapor transmission will be the most comfortable.

Release Liner:

When designing a backing layer, the material's chemical resistance is the most important consideration. The most comfortable backing will have the lowest modulus, or high flexibility, good oxygen transmission, and a high rate of moisture vapor transmission.

Other excipients:

Drug reservoirs are prepared using a variety of solvents, including dichloromethane, methanol, acetone, isopropanol, and chloroform. To give the transdermal patch flexibility, plasticizers like di-butylpthalate, triethyl citrate, polyethylene glycol, and propylene glycol are also added.

Evaluation of transdermal patches: -These studies are predictive of transdermal dosage forms and can be classified into following types:

1. Physicochemical evaluation
2. In vitro evaluation
3. In vivo evaluation

Physicochemical evaluation: -

Thickness: A traveling microscope, dial gauge, screw gauge, or micrometer is used to measure the thickness of transdermal film at various film locations.

Uniformity of weight: A digital weighing machine was used to weigh each patch in order to conduct a weight variation test. For every formulation, the measurements were made in triplicate. Next, the average weight and standard deviation were computed. Folding Endurance: The purpose of this test was to evaluate the strength of the patch made with various polymers and the effectiveness of the plasticizer. The number of folds needed to shatter any polymeric patch is known as folding endurance.

Drug content determination: A precisely weighed amount of film (roughly 100 mg) is dissolved in 100 mL of an appropriate drug-soluble solvent, and the mixture is then continuously shaken for 24 hours in a shaker incubator. After that, the entire mixture is sonicated. The drug in solution is measured spectrophotometrically using the proper dilution following sonication and filtration.

Moisture content: The prepared films are weighed separately and stored for 24 hours at room temperature in a desiccator with calcium chloride. After a predetermined amount of time, the films are weighed once more until their weight remains constant. Surface pH: For one hour, patches were placed in glass tubes with 0.5 ml of doubledistilled water and allowed to swell. After a minute of equilibration, a combined glass electrode was brought close to the patch's surface, and pH readings were obtained.

In vitro evaluation: -

Two features of the dosage forms that are crucial in characterizing the drug dissolution profile from controlled release dosage forms and, consequently, there in vivo performance are drug release mechanisms and kinetics. The drug release rate of TDDS can be determined using a variety of techniques, and several mathematical models have been developed to describe the drug dissolution kinetics from controlled release drug delivery systems.

To evaluate the effectiveness, risk, side effects, patient compliance, etc., clinical trials have been carried out. Phase II clinical trials assess short-term safety and primarily efficacy in patients, while phase I clinical trials focus primarily on safety in volunteers. Phase IV trials are conducted at post-marketing surveillance for marketed patches to identify adverse drug reactions, while phase III trials show the safety and efficacy in a large patient population. [23, 24]

In vivo evaluation: -

The real representation of the drug's performance is found in in vivo evaluations. In vivo studies allow for a thorough exploration of the variables that cannot be considered in in vitro studies. TDDS can be evaluated in vivo using the following methods: [25]

CONCLUSION

The controlled and continuous delivery of drugs into the systemic circulation is made possible by the transdermal drug delivery system (TDDS), an efficient, secure, and patient-friendly technique. TDDS is especially useful for antifungal agents because it avoids first-pass metabolism, lessens gastrointestinal irritation, and keeps drug levels constant, all of which increase therapeutic efficacy.

Transdermal patches present a promising and cutting-edge alternative for antifungal therapy in light of the growing prevalence of fungal infections, the scarcity of effective medications, and the rise in resistance. The potential of TDDS has been further enhanced by the use of polymer matrices, permeation enhancers, and cutting-edge technologies like microneedles and 3D printing.

TDDS is still developing and has great potential as a dependable and cutting-edge platform for upcoming antifungal treatments, despite issues like skin permeability, drug potency, and local irritation.

REFERENCES

1. Chen SC, Sorrell TC. Antifungal agents. Med J August 2007; 187:404-9.
2. Yamamoto         T,         Kata    Kabe    K, Akiyoshi    K,        Kan     K         and Asano    T. Topical Application           of

         Glibenclamide Lowers Blood Glucose Levels in Rats.Diabetes Res.Clin. Pract.1990; 8:19- 22.

3. Rhaghuram Rk, Muttalik S, Reddy S. Once – Daily Sustained- Release Matrix Tablets of Nicorandil: Formulation and Invitro Evaluation. Aaps Pharm.Scitech. 2003; 4(4):480– 488.
4. Shaila L, Pandey S, Udupa N. Design and Evaluation of Matrix Type Membrane Controlled Transdermal Drug Delivery System of Nicotine Suitable for Use in Smoking Cessation. Indian Journal of Pharmaceutical Sciences. 2006; 68:179- 184.
5. Aarti N, Louk Armp, Russsel Op. Richard Hg. Mechanism of Oleic Acid Induced Skin

          Permeation Enhancement in Vivo in Humans. Jour. Control. Release. 1995; 37:299306.

6. Detandt M, Nolard N. Fungal contamination of the floors of swimming pools, particularly subtropical swimming paradises. Mycoses 1995; 38:509-13.
7. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by nondermatophytic molds: Clinical features and response to treatment of 59 cases. J Am Acad Dermatol 2000; 42:217-24.
8. Greer DL.          Evolving         role of nondermatophytes in onychomycosis. Int   JDermatol 1995; 34:521-4.
9. Velegraki As, Cafarchia C, Gaitanis G, Iatta R, Boekhout T. Malassezia infections in humans and animals: Pathophysiology, detection, and treatment. PLoS Pathog 2015;11: e1004523.
10. Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 2016; 214:15-21.
11. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999; 78:123-38.
12. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbial Rev 2007; 20:133-63.
13. Wiechers           J.         Use      of         Chemical        Penetration     Enhancers   inTransdermal Drug Delivery Possibilities and Difficulties. Acta Pharm. 1992: 4: 123.
14. Ghosh B, Preethi Gb, Mishra R, Parcha V. Transdermal Delivery of Ibuprofen and ItsProdrugs by Passive Diffusion and Iontophoresis. Int J Pharm Pharm Sci. 2010; 2(1):79-85.
15. Rajesh N, Siddaramaiah, Gowda Dv, Somashekar Cn. Formulation and Evaluation ofBiopolymer Based Transdermal Drug Delivery. Int J Pharm Pharm Sci. 2010; 2(2):142147.
16. Sinha Vr, Kaur Pm Permeation Enhancers for Transdermal Drug Delivery. Drug Dev Ind Pharm. 2000; 26: 1131–40.
17. Barry Bw., The Lpp Theory of Skin Penetration Enhancement. Maturitas. 1998; 29: 165–85.
18. Ghafourian T, Zandasrar P, Hamishekar H, Nokhodchi A, the Effect of Penetration Enhancers on Drug Delivery Through Skin: A Qsar Study. J Control Release.2004; 99: 113–25.
19. Montia D, Saettone Mf, Giannaccini B, Angeli Dg, Enhancement of Transdermal Penetration of Dapiprazole Through Hairless Mouse Skin. J Control Release.1995; 33: 71–7.
20. Bharadwaj S, Gupta Gd, Sharma Vk. Topical Gel: A Novel Approach for Drug Delivery. J Chem. Bio. Phy. Sci. 2012; 2(2): 856-867.
21. Sharma N, Parashar B, Sharma S, Mahajan U. Blooming Pharma Industry with Transdermal Drug Delivery System. Indo Global J Pharm. Sci. 2012; 2(3): 262-278.
22. Kusum Devi and Dr.K.L.K. paranjothi, Development and Evaluation of free films and Transdermal patches of Ketorolac Tromethamine using polymers and pressure sensitive Adhesives the Eastern pharmacist, XLI, No. 485, 1998, 97-100.
23. Singh M.C., Naik A.S and Sawant S.D., Transdermal Drug Delivery Systems with Major Emphasis on Transdermal Patches: A Review. Journal of Pharmacy Research. 2010; 3(10): 25372543.
24. Al- Khamis K, Davis S.S and Hadgraft J. Microviscosity and Drug Release from Topical Gel Formulations. Pharm. Res. 1986; 3: 214-217.
25. Vishvakarama P, Agarwal S, Sharma R, Sharma S. Transdermal Drug Delivery System Review. Int. J. Res.Pharm. 2012; 3(5):50-3.
26. S. Seyedmousavi, H. Rafati, M. Ilkit, A. Tolooe, M.T. Hedayati, P. Verweij, Systemic antifungal agents: current status and projected future developments, in: T. Lion (Ed.), Human Fungal Pathogen Identification: Methods and Protocols, Springer New York, New York, NY, 2017, pp 107-139.
27. Lucca AJ. De, Harmful fungi in both agriculture and medicine, Rev. Iberoam. Micol. 24 (1) (2007) 3.
28. B. Imko-Walczuk, A. Okuniewska, A. Pr?dota-G?owacka, J. Ja´skiewicz, W. Placek, Z. W?odarczyk, et al. (Eds.), Benign Cutaneous Disease Among Polish Renal Transplant Recipients. Transplant Proc, Elsevier, 2016.
29. M.Swidergsll, M.khalaji,N.V.Solis,D.L.Moyes,R.A.Drummond,B.Hube,et al.,Candidalysin is requrie for neutrophill recruitment and virulence during sytemic candida albicans infection,j.infect. Dis,220(9) (2019)1477-1488.
30. T. Li, L. Li, F. Du, L. Sun, J. Shi, M. Long, et al., Activity and mechanism of action of antifungal peptides from microorganisms: a review, Molecules (Basel) 26 (11) (2021) 3438.
31. DdN. Alves, A.R. Ferreira, A.B.S. Duarte, A.K.V. Melo, D.P. de Sousa, RDd Castro, Breakpoints for the classification of anti-Candida compounds in antifungal screening, BioMed Res. Int. 2021 (1) (2021) 6653311.
32. Vena, P. Munoz, ˜ M. Mateos, J. Guinea, A. Galar, F. Pea, et al., Therapeutic drug monitoring of antifungal drugs: another tool to improve patient outcome? Infect. Dis. Ther. 9 (2020) 137– 149.
33. A. Gomez-Lopez, Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation, Clin. Microbiol. Infect. 26 (11) (2020) 1481–1487.
34. J.S. Passos, L.C. de Martino, V.F.C. Dartora, G.L. de Araujo, K. Ishida, L.B. Lopes, Development, skin targeting and antifungal efficacy of topical lipid nanoparticles containing itraconazole, Eur. J. Pharmaceut. Sci. 149 (2020) 105296.
35. Zaid Alkilani, R. Hamed, B. Musleh, Z. Sharaire, Breaking boundaries: the advancements in transdermal delivery of antibiotics, Drug Deliv. 31 (1) (2024) 2304251.
36. M. Shafiei, L. Peyton, M. Hashemzadeh, A. Foroumadi, History of the development of antifungal azoles: a review on structures, SAR, and mechanism of action, Bioorg. Chem. 104 (2020) 104240.
37. S. Hasim, J.J. Coleman, Targeting the fungal cell wall: current therapies and implications for development of alternative antifungal agents, Future Med. Chem. 11 (8) (2019) 869–883.
38. J. Hou?s?, J. Spí?zek, V. Havlí?cek, Antifungal drugs, Metabolites 10 (3) (2020) 106.
39. S.C. Chen, T.C. Sorrell, Antifungal agents, Med. J. Aust. 187 (7) (2007) 404.
40. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Ketoconazole (2024) [Available from: https://pubchem.ncbi.nlm.nih. gov/compound/Nizoral.
41. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Miconazole (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/ compound/Miconazole.
42. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Clotrimazole (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/compo und/Clotrimazole.
43. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Econazole (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/compoun d/Econazole.
44. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Fluconazole (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/comp ound/Fluconazole.
45. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Itraconazole (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/compo und/Itraconazole.
46. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Voriconazole (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/compo und/Voriconazole.
47. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Posaconazole (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/compo und/Posaconazole.
48. J. Wang, Z. Jin, X. Xu, Gamma-cyclodextrin on enhancement of water solubility and store stability of nystatin, J. Incl. Phenom. Macrocycl. Chem. 78 (1) (2014) 145–150.
49. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Nystatin (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/compound /Nystatin.
50. S. Fang, X. Peng, X. Liang, J. Shen, J. Wang, J. Chen, et al., Enhancing water solubility and stability of natamycin by molecular encapsulation in methylβ-cyclodextrin and its mechanisms by molecular dynamics simulations, Food Biophys. 15 (2020).
51. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Natamycin (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/compoun d/Natamycin.
52. J. Torrado, R. Espada, M. Ballesteros, S. Torrado-Santiago, Amphotericin B formulations and drug targeting, J. Pharmaceut. Sci. 97 (7) (2008) 2405–2425.
53. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Amphotericin B (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/co mpound/Amphotericin-B.
54. M. Szymanski, ´ S. Chmielewska, U. Czyzewska, ? M. Malinowska, A. Tylicki,Echinocandins–structure, mechanism of action and use in antifungal therapy, J. Enzym. Inhib.Med. Chem. 37 (1) (2022) 876–894.
55. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Caspofungin (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/comp ound/Caspofungin.
56. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Micafungin (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/ compound/Micafungin.
57. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Anidulafungin (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/com pound/Anidulafungin.
58. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Terbinafine (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/comp ound/Terbinafine.
59. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Naftifine (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Naftifine.
60. S. Rao, T. Barot, K. Rajesh, L.L. Jha, Formulation, optimization and evaluation of microemulsion based gel of Butenafine Hydrochloride for topical delivery by using simplex lattice mixture design, J. Pharm. Investig. 46 (1) (2016) 1–12.
61. W.A. Mahdi, S.I. Bukhari, S.S. Imam, S. Alshehri, A. Zafar, M. Yasir, Formulation and optimization of butenafine-loaded topical nano lipid carrier-based gel: characterization, irritation study, and anti-fungal activity, Pharmaceutics 13 (7) (2021) 1087.
62. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Flucytosine (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/comp ound/Flucytosine.
63. Griseofulvin. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center, for Biotechnology Information, 2024 [Available from: https ://pubchem.ncbi.nlm.nih.gov/compound/Griseofulvin.
64. PubChem [Internet], Bethesda (MD): national library of medicine (US) NCfBI, Tolnaftate (2024) [Available from: https://pubchem.ncbi.nlm.nih.gov/ compound/Tolnafta.